P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

February 2008

Features

Editor’s Memo

The Language of (Forgive Us) Change, As P&T Enters the Digital Age

We know you’re as sick of the word “change” as we are, but like many clichés, it serves its purpose. Oh, and by the way, P&T is going digital.
Sonja Sherritze

Use and Outcomes of Antifibrinolytic Therapy in Patients Undergoing Cardiothoracic Surgery at 20 Academic Medical Centers in the United States

Given the association between the use of aprotinin (Trasylol) and an increased risk of adverse events among cardiothoracic surgery patients, in contrast to a lack of elevated risk for aminocaproic acid and tranexamic acid, the authors suggest that hospitals examine their current patterns of use and perhaps restrict aprotinin for these patients to prevent major blood loss.
Karl Matuszewski, MS, PharmD; Robert Schoenhaus, PharmD; Mary Ellen Bonk, PharmD; James Lane, PharmD; and Michael Oinonen, PharmD, MPH

Evaluation of the Management of Acute Venous Thromboembolism and Its Outcomes: One Institution’s Experience

The authors describe a study in which they sought to determine whether ­standard practice guidelines for the care of patients with VTE were being ­followed at their VA center.
Cristin Williams, PharmD, Ji Koo, PharmD, and Jonathan Hass, PharmD

Meeting Highlights

American Society of Hematology, 49th Annual Meeting

Presentations cover lenalidomide (Revlimid) in the treatment of multiple myeloma, eculizumab (Soliris) for paroxysmal nocturnal hemolysis, RAD001 (Everolimus) for lymphoma, the use of deferasirox (Exjade) in patients with iron overload, and dasatinib (Sprycel) and nilotinib (Tasigna) for chronic myelogenous leukemia.
Walter Alexander

Pharmaceutical Approval Update

Topics include sapropterin dihydrochloride tablets (Kuvan) for reducing phenyl­alanine levels in patients with phenylketonuria; nebivolol (Bystolic) for hyper­tension; and a starch infusion (Voluven) to prevent decreased blood volume ­during surgery.
Marvin M. Goldenberg, PhD, RPh, MS

Departments

Editorial

Health 3.0

David Nash, MD, MBA, discusses the challenges and benefits of “mobile social networking” in the digital age of constant connectedness and its potential effect on the future of medicine.
David Nash, MD, MBA

Medication Errors

Adding Lidocaine to IV Potassium Infusions Can Cause Safety Problems

Matthew Grissinger, RPh, FASCP, reports on the problems involved when lidocaine is added to IV potassium chloride.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

Off-Label Drug Promotion Now on the Table

Stephen Barlas details the problems that might arise if drug manufacturers are permitted to market drugs for off-label purposes, especially antipsychotic agents, and the concerns of Congress that clinical trials will be lacking to support the new indications.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

From aliskiren to Welchol, P&T presents the latest information on FDA approvals, indications, and industry updates.

Drug Forecast

Aliskiren (Tekturna), A Novel Antihypertensive Approach to Inhibition of the Renin– ­Angiotensin–Aldosterone System

Authors Cromer and Peker review aliskiren (Tekturna) for hypertension.
Julie Cromer, PharmD, and Simona Peker, BS, MS/MLS, MSA, PharmD